US 2016/0256537 A1 · INFLUENZA VACCINE

Abstract

The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from an influenza virus strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant comprising a metabolisable oil, a sterol and/or a tocopherol such as alpha tocopherol, and an emulsifying agent.

Claims21

Dependent claims

A method for immunizing a human against influenza virus infection, the method comprising;

selecting a human who was previously vaccinated with a monovalent first vaccine composition comprising a low amount of a influenza virus antigen or antigenic preparation from a first variant of an influenza virus subtype that is associated with a pandemic or that has the potential to be associated with a pandemic, in combination with an adjuvant, wherein the low antigen amount does not exceed 15 μg of HA per dose, and wherein said adjuvant is an oil-in-water emulsion comprising squalene and an emulsifying agent;
and
administering to the selected human a second vaccine composition comprising an influenza virus antigen or antigenic preparation from a second variant of the same influenza virus subtype.

Dependencies are inferred from the claim text.

Facts

Application

14/996,446Filed 15 Jan 2016

Priority

GB 0618195.215 Sep 2006

Published

8 Sep 2016

Term ends

Not estimatedThe source records don’t support an estimate.

Classification17 codes

A61K 39/145
Viral antigens: orthomyxoviridae, e.g. influenza virus
A61K 39/12
Medicinal preparations containing antigens or antibodies: viral antigens
A61K 39/39
Medicinal preparations containing antigens or antibodies: characterised by the immunostimulating additives, e.g. chemical adjuvants
A61P 31/16
For RNA viruses: for influenza or rhinoviruses

Family

Application60/831,437Us provisional application · filed 17 Jul 2006

Application11/692,792Continuation · filed 28 Mar 2007

Application13/163,002Continuation · filed 17 Jun 2011

Application14/996,446Continuation

US 2008/0014217 A1Published application

US 2011/0243987 A1Published application

US 9,278,127 B2Related patent

US 9,943,588 B2Related patent

US 2016/0256537 A1This patent

From the US filing history. Foreign family members aren’t listed.

Influenza vaccine

Life of this patent

Influenza vaccine

Life of this patent

Abstract

Claims21